Practice Parameter:Treatment of parkinson disease with motor fluctuations and dyskinesia (an evidence-based review) : Report of the quality standards subcommittee of the american academy of neurology
Identifieur interne : 002909 ( Main/Exploration ); précédent : 002908; suivant : 002910Practice Parameter:Treatment of parkinson disease with motor fluctuations and dyskinesia (an evidence-based review) : Report of the quality standards subcommittee of the american academy of neurology
Auteurs : R. Pahwa [États-Unis] ; S. A. Factor [États-Unis] ; K. E. Lyons [États-Unis] ; W. G. Ondo [États-Unis] ; G. Gronseth [États-Unis] ; H. Bronte-Stewart [États-Unis] ; M. Hallett [États-Unis] ; J. Miyasaki [Canada] ; J. Stevens [États-Unis] ; W. J. Weiner [États-Unis]Source :
- Neurology [ 0028-3878 ] ; 2006.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Neurologie.
English descriptors
- KwdEn :
Abstract
Objective: To make evidence-based treatment recommendations for the medical and surgical treatment of patients with Parkinson disease (PD) with levodopa-induced motor fluctuations and dyskinesia. To that end, five questions were addressed. 1. Which medications reduce off time? 2. What is the relative efficacy of medications in reducing off time? 3. Which medications reduce dyskinesia? 4. Does deep brain stimulation (DBS) of the subthalamic nucleus (STN), globus pallidus interna (GPi), or ventral intermediate (VIM) nucleus of the thalamus reduce off time, dyskinesia, and antiparkinsonian medication usage and improve motor function? 5. Which factors predict improvement after DBS? Methods: A 10-member committee including movement disorder specialists and general neurologists evaluated the available evidence based on a structured literature review including MEDLINE, EMBASE, and Ovid databases from 1965 through June 2004. Results, Conclusions, and Recommendations: 1. Entacapone and rasagiline should be offered to reduce off time (Level A). Pergolide, pramipexole, ropinirole, and tolcapone should be considered to reduce off time (Level B). Apomorphine, cabergoline, and selegiline may be considered to reduce off time (Level C). 2. The available evidence does not establish superiority of one medicine over another in reducing off time (Level B). Sustained release carbidopa/levodopa and bromocriptine may be disregarded to reduce off time (Level C). 3. Amantadine may be considered to reduce dyskinesia (Level C). 4. Deep brain stimulation of the STN may be considered to improve motor function and reduce off time, dyskinesia, and medication usage (Level C). There is insufficient evidence to support or refute the efficacy of DBS of the GPi or VIM nucleus of the thalamus in reducing off time, dyskinesia, or medication usage, or to improve motor function. 5. Preoperative response to levodopa predicts better outcome after DBS of the STN (Level B).
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000841
- to stream PascalFrancis, to step Curation: 000482
- to stream PascalFrancis, to step Checkpoint: 000703
- to stream Main, to step Merge: 002C01
- to stream Main, to step Curation: 002909
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Practice Parameter:Treatment of parkinson disease with motor fluctuations and dyskinesia (an evidence-based review) : Report of the quality standards subcommittee of the american academy of neurology</title><author><name sortKey="Pahwa, R" sort="Pahwa, R" uniqKey="Pahwa R" first="R." last="Pahwa">R. Pahwa</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of Kansas Medical Center</s1><s2>Kansas City</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>University of Kansas Medical Center</wicri:noRegion></affiliation></author><author><name sortKey="Factor, S A" sort="Factor, S A" uniqKey="Factor S" first="S. A." last="Factor">S. A. Factor</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Emory University School of Medicine</s1><s2>Atlanta, GA</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Emory University School of Medicine</wicri:noRegion></affiliation></author><author><name sortKey="Lyons, K E" sort="Lyons, K E" uniqKey="Lyons K" first="K. E." last="Lyons">K. E. Lyons</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of Kansas Medical Center</s1><s2>Kansas City</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>University of Kansas Medical Center</wicri:noRegion></affiliation></author><author><name sortKey="Ondo, W G" sort="Ondo, W G" uniqKey="Ondo W" first="W. G." last="Ondo">W. G. Ondo</name><affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Baylor College of Medicine</s1><s2>Houston, TX</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university">Baylor College of Medicine</orgName></affiliation></author><author><name sortKey="Gronseth, G" sort="Gronseth, G" uniqKey="Gronseth G" first="G." last="Gronseth">G. Gronseth</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of Kansas Medical Center</s1><s2>Kansas City</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>University of Kansas Medical Center</wicri:noRegion></affiliation></author><author><name sortKey="Bronte Stewart, H" sort="Bronte Stewart, H" uniqKey="Bronte Stewart H" first="H." last="Bronte-Stewart">H. Bronte-Stewart</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Stanford University Hospital</s1><s2>San Francisco, CA</s2><s3>USA</s3><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Stanford University Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Hallett, M" sort="Hallett, M" uniqKey="Hallett M" first="M." last="Hallett">M. Hallett</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>National Institutes of Health</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>National Institutes of Health</wicri:noRegion></affiliation></author><author><name sortKey="Miyasaki, J" sort="Miyasaki, J" uniqKey="Miyasaki J" first="J." last="Miyasaki">J. Miyasaki</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Toronto Western Hospital</s1><s3>CAN</s3><sZ>8 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Toronto Western Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Stevens, J" sort="Stevens, J" uniqKey="Stevens J" first="J." last="Stevens">J. Stevens</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Fort Wayne Neurological Center</s1><s2>Fort Wayne, IN</s2><s3>USA</s3><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Fort Wayne Neurological Center</wicri:noRegion></affiliation></author><author><name sortKey="Weiner, W J" sort="Weiner, W J" uniqKey="Weiner W" first="W. J." last="Weiner">W. J. Weiner</name><affiliation wicri:level="3"><inist:fA14 i1="08"><s1>University of Maryland School of Medicine</s1><s2>Baltimore</s2><s3>USA</s3><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Baltimore</settlement><region type="state">Maryland</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">06-0225668</idno><date when="2006">2006</date><idno type="stanalyst">PASCAL 06-0225668 INIST</idno><idno type="RBID">Pascal:06-0225668</idno><idno type="wicri:Area/PascalFrancis/Corpus">000841</idno><idno type="wicri:Area/PascalFrancis/Curation">000482</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000703</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000703</idno><idno type="wicri:doubleKey">0028-3878:2006:Pahwa R:practice:parameter:treatment</idno><idno type="wicri:Area/Main/Merge">002C01</idno><idno type="wicri:Area/Main/Curation">002909</idno><idno type="wicri:Area/Main/Exploration">002909</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Practice Parameter:Treatment of parkinson disease with motor fluctuations and dyskinesia (an evidence-based review) : Report of the quality standards subcommittee of the american academy of neurology</title><author><name sortKey="Pahwa, R" sort="Pahwa, R" uniqKey="Pahwa R" first="R." last="Pahwa">R. Pahwa</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of Kansas Medical Center</s1><s2>Kansas City</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>University of Kansas Medical Center</wicri:noRegion></affiliation></author><author><name sortKey="Factor, S A" sort="Factor, S A" uniqKey="Factor S" first="S. A." last="Factor">S. A. Factor</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Emory University School of Medicine</s1><s2>Atlanta, GA</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Emory University School of Medicine</wicri:noRegion></affiliation></author><author><name sortKey="Lyons, K E" sort="Lyons, K E" uniqKey="Lyons K" first="K. E." last="Lyons">K. E. Lyons</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of Kansas Medical Center</s1><s2>Kansas City</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>University of Kansas Medical Center</wicri:noRegion></affiliation></author><author><name sortKey="Ondo, W G" sort="Ondo, W G" uniqKey="Ondo W" first="W. G." last="Ondo">W. G. Ondo</name><affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Baylor College of Medicine</s1><s2>Houston, TX</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university">Baylor College of Medicine</orgName></affiliation></author><author><name sortKey="Gronseth, G" sort="Gronseth, G" uniqKey="Gronseth G" first="G." last="Gronseth">G. Gronseth</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of Kansas Medical Center</s1><s2>Kansas City</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>University of Kansas Medical Center</wicri:noRegion></affiliation></author><author><name sortKey="Bronte Stewart, H" sort="Bronte Stewart, H" uniqKey="Bronte Stewart H" first="H." last="Bronte-Stewart">H. Bronte-Stewart</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Stanford University Hospital</s1><s2>San Francisco, CA</s2><s3>USA</s3><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Stanford University Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Hallett, M" sort="Hallett, M" uniqKey="Hallett M" first="M." last="Hallett">M. Hallett</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>National Institutes of Health</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>National Institutes of Health</wicri:noRegion></affiliation></author><author><name sortKey="Miyasaki, J" sort="Miyasaki, J" uniqKey="Miyasaki J" first="J." last="Miyasaki">J. Miyasaki</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Toronto Western Hospital</s1><s3>CAN</s3><sZ>8 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Toronto Western Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Stevens, J" sort="Stevens, J" uniqKey="Stevens J" first="J." last="Stevens">J. Stevens</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Fort Wayne Neurological Center</s1><s2>Fort Wayne, IN</s2><s3>USA</s3><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Fort Wayne Neurological Center</wicri:noRegion></affiliation></author><author><name sortKey="Weiner, W J" sort="Weiner, W J" uniqKey="Weiner W" first="W. J." last="Weiner">W. J. Weiner</name><affiliation wicri:level="3"><inist:fA14 i1="08"><s1>University of Maryland School of Medicine</s1><s2>Baltimore</s2><s3>USA</s3><sZ>10 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Baltimore</settlement><region type="state">Maryland</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Neurology</title><title level="j" type="abbreviated">Neurology</title><idno type="ISSN">0028-3878</idno><imprint><date when="2006">2006</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Neurology</title><title level="j" type="abbreviated">Neurology</title><idno type="ISSN">0028-3878</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>American</term><term>Dyskinesia</term><term>Fluctuations</term><term>Nervous system diseases</term><term>Neurology</term><term>Parkinson disease</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term><term>Parkinson maladie</term><term>Dyskinésie</term><term>Traitement</term><term>Fluctuation</term><term>Américain</term><term>Neurologie</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Neurologie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objective: To make evidence-based treatment recommendations for the medical and surgical treatment of patients with Parkinson disease (PD) with levodopa-induced motor fluctuations and dyskinesia. To that end, five questions were addressed. 1. Which medications reduce off time? 2. What is the relative efficacy of medications in reducing off time? 3. Which medications reduce dyskinesia? 4. Does deep brain stimulation (DBS) of the subthalamic nucleus (STN), globus pallidus interna (GPi), or ventral intermediate (VIM) nucleus of the thalamus reduce off time, dyskinesia, and antiparkinsonian medication usage and improve motor function? 5. Which factors predict improvement after DBS? Methods: A 10-member committee including movement disorder specialists and general neurologists evaluated the available evidence based on a structured literature review including MEDLINE, EMBASE, and Ovid databases from 1965 through June 2004. Results, Conclusions, and Recommendations: 1. Entacapone and rasagiline should be offered to reduce off time (Level A). Pergolide, pramipexole, ropinirole, and tolcapone should be considered to reduce off time (Level B). Apomorphine, cabergoline, and selegiline may be considered to reduce off time (Level C). 2. The available evidence does not establish superiority of one medicine over another in reducing off time (Level B). Sustained release carbidopa/levodopa and bromocriptine may be disregarded to reduce off time (Level C). 3. Amantadine may be considered to reduce dyskinesia (Level C). 4. Deep brain stimulation of the STN may be considered to improve motor function and reduce off time, dyskinesia, and medication usage (Level C). There is insufficient evidence to support or refute the efficacy of DBS of the GPi or VIM nucleus of the thalamus in reducing off time, dyskinesia, or medication usage, or to improve motor function. 5. Preoperative response to levodopa predicts better outcome after DBS of the STN (Level B).</div></front></TEI><affiliations><list><country><li>Canada</li><li>États-Unis</li></country><region><li>Maryland</li><li>Texas</li></region><settlement><li>Baltimore</li><li>Houston</li></settlement><orgName><li>Baylor College of Medicine</li></orgName></list><tree><country name="États-Unis"><noRegion><name sortKey="Pahwa, R" sort="Pahwa, R" uniqKey="Pahwa R" first="R." last="Pahwa">R. Pahwa</name></noRegion><name sortKey="Bronte Stewart, H" sort="Bronte Stewart, H" uniqKey="Bronte Stewart H" first="H." last="Bronte-Stewart">H. Bronte-Stewart</name><name sortKey="Factor, S A" sort="Factor, S A" uniqKey="Factor S" first="S. A." last="Factor">S. A. Factor</name><name sortKey="Gronseth, G" sort="Gronseth, G" uniqKey="Gronseth G" first="G." last="Gronseth">G. Gronseth</name><name sortKey="Hallett, M" sort="Hallett, M" uniqKey="Hallett M" first="M." last="Hallett">M. Hallett</name><name sortKey="Lyons, K E" sort="Lyons, K E" uniqKey="Lyons K" first="K. E." last="Lyons">K. E. Lyons</name><name sortKey="Ondo, W G" sort="Ondo, W G" uniqKey="Ondo W" first="W. G." last="Ondo">W. G. Ondo</name><name sortKey="Stevens, J" sort="Stevens, J" uniqKey="Stevens J" first="J." last="Stevens">J. Stevens</name><name sortKey="Weiner, W J" sort="Weiner, W J" uniqKey="Weiner W" first="W. J." last="Weiner">W. J. Weiner</name></country><country name="Canada"><noRegion><name sortKey="Miyasaki, J" sort="Miyasaki, J" uniqKey="Miyasaki J" first="J." last="Miyasaki">J. Miyasaki</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002909 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002909 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:06-0225668
|texte= Practice Parameter:Treatment of parkinson disease with motor fluctuations and dyskinesia (an evidence-based review) : Report of the quality standards subcommittee of the american academy of neurology
}}
| This area was generated with Dilib version V0.6.29. |  |